ATLASNeurocrine Biosciences (NBIX) Q3 2026 earnings results
Neurocrine Biosciences (NBIX) reported EPS of $3.29 against an analyst estimate of $2.75: a beat of $0.54 (19.6%). The quarter ended Sep 30, 2026; the company reported on Monday, November 2, 2026, after the close.
Status: Confirmed · 16:45 ET, Nov 2 · revised Nov 2, 2026 · Source: EODHD (calendar and fundamentals, cross-checked)
Notify me when Neurocrine Biosciences reports
Track NBIX free Add Neurocrine Biosciences to a free ATLAS watchlist.
NBIX Q3 2026 results at a glance
| EPS reported | $3.29 |
|---|---|
| EPS estimate | $2.75 |
| Surprise | Beat · +$0.54 (+19.6%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 2, 2026, after the close |
| Status | Confirmed · 16:45 ET, Nov 2 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Neurocrine Biosciences’s Q3 2026, a calendar-year company.
Neurocrine Biosciences EPS surprise history: last 4 quarters
Neurocrine Biosciences beat the EPS estimate in 4 of its last 4 reports, with an average surprise of +24.0%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 2, 2026 | $2.75 | $3.29 | +19.6% | Beat | – |
| Jul 30, 2026 | $1.96 | $2.85 | +45.4% | Beat | -7.7% |
| May 5, 2026 | $1.70 | $1.94 | +14.1% | Beat | +9.7% |
| Feb 27, 2026 | $0.18 | $0.21 | +16.7% | Beat | +1.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
NBIX stock reaction to the report
The price reaction will be added after the Nov 3, 2026 close.
This section appears once a post-report closing price exists and updates with every new close.
Next NBIX earnings report
Neurocrine Biosciences has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the NBIX earnings calendar.
ATLAS fair value and signal for NBIX
| Last price | $145.34 (-0.5%) |
|---|---|
| ATLAS fair value | $279.82 (range $171.40–$456.82) · price is 48% below it |
| Chance of a higher close in 1 month | 52% (normal range $138.92–$152.86) |
These are model outputs from the same valuation and calibrated model as the Neurocrine Biosciences stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Neurocrine Biosciences Q3 2026 earnings: frequently asked questions
Did Neurocrine Biosciences beat earnings estimates for Q3 2026?
Neurocrine Biosciences reported EPS of $3.29 against an analyst estimate of $2.75: a beat of $0.54 (19.6%).
When did Neurocrine Biosciences report Q3 2026 results?
Neurocrine Biosciences reported on Monday, November 2, 2026, after the close, for the quarter ended Wednesday, September 30, 2026.
How often does NBIX beat EPS estimates?
In its last 4 reports with a recorded result, Neurocrine Biosciences beat the EPS estimate 4 times; the average surprise was +24.0%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer